Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]
Jones G, Panova E, Day R. Drug Des Devel Ther. 2017;11:3077–3081.On page 3078, Table 1, Abbreviation list, expansion for FBX was incorrectly listed as feboxustat, the correct spelling is febuxostat.Read the original article
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-12-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | https://www.dovepress.com/corrigendum-for-the-management-of-gout-role-of-combinat-peer-reviewed-article-DDDT |
| id |
doaj-8030f8a402ba419cb3ec926780e4c161 |
|---|---|
| record_format |
Article |
| spelling |
doaj-8030f8a402ba419cb3ec926780e4c1612020-11-24T22:54:19ZengDove Medical PressDrug Design, Development and Therapy1177-88812017-12-01Volume 113589359036039Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]Jones GPanova EDay RJones G, Panova E, Day R. Drug Des Devel Ther. 2017;11:3077–3081.On page 3078, Table 1, Abbreviation list, expansion for FBX was incorrectly listed as feboxustat, the correct spelling is febuxostat.Read the original articlehttps://www.dovepress.com/corrigendum-for-the-management-of-gout-role-of-combinat-peer-reviewed-article-DDDT |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Jones G Panova E Day R |
| spellingShingle |
Jones G Panova E Day R Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum] Drug Design, Development and Therapy |
| author_facet |
Jones G Panova E Day R |
| author_sort |
Jones G |
| title |
Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum] |
| title_short |
Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum] |
| title_full |
Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum] |
| title_fullStr |
Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum] |
| title_full_unstemmed |
Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum] |
| title_sort |
guideline development for the management of gout: role of combination therapy with a focus on lesinurad [corrigendum] |
| publisher |
Dove Medical Press |
| series |
Drug Design, Development and Therapy |
| issn |
1177-8881 |
| publishDate |
2017-12-01 |
| description |
Jones G, Panova E, Day R. Drug Des Devel Ther. 2017;11:3077–3081.On page 3078, Table 1, Abbreviation list, expansion for FBX was incorrectly listed as feboxustat, the correct spelling is febuxostat.Read the original article |
| url |
https://www.dovepress.com/corrigendum-for-the-management-of-gout-role-of-combinat-peer-reviewed-article-DDDT |
| work_keys_str_mv |
AT jonesg guidelinedevelopmentforthemanagementofgoutroleofcombinationtherapywithafocusonlesinuradcorrigendum AT panovae guidelinedevelopmentforthemanagementofgoutroleofcombinationtherapywithafocusonlesinuradcorrigendum AT dayr guidelinedevelopmentforthemanagementofgoutroleofcombinationtherapywithafocusonlesinuradcorrigendum |
| _version_ |
1725660705289404416 |